Changes in calcium regulation contribute to loss of contractile function in dilated cardiomyopathy. Clinical treatment using β-adrenergic receptors antagonists (β-blockers) slows deterioration of cardiac function in end-stage heart failure patients; however, the effects of β-blocker treatment on calcium dynamics in the failing heart are unknown. To address this issue, tropomodulin overexpressing transgenic (TOT) mice, which suffer from dilated cardiomyopathy, were treated with a nonselective β-receptor blocker (propranolol; 5mg/kg/day) for two weeks. Calcium dynamics in isolated cardiomyocytes of TOT mice significantly improved after treatment compared to untreated TOT mice. Frequency-dependent diastolic and calcium transient amplitudes were returned to normal in propranolol treated TOT mice and not untreated TOT mice. Calcium kinetic measurements of time to peak and t 50 relaxation were also normalized. Immunoblot analysis of untreated TOT heart samples showed a 3.6 fold reduction of sarcoplasmic-reticulum calcium ATPase (SERCA) while sodium-calcium exchanger (NCX) were increased 2.6 fold relative to nontransgenic samples. Propranolol treatment of TOTs reversed the alterations in SERCA and NCX protein levels, but not potassium channels. Although restoration of calcium dynamics occurred within two weeks of β-blockade treatment, evidence of functional improvement in cardiac contractility assessed by echocardiography took ten weeks to materialize. These results demonstrate that β-adrenergic blockade restores calcium dynamics and normalizes expression of calcium-handling proteins, eventually leading to improved hemodynamic function in cardiomyopathic hearts.
INTRODUCTION
Heart failure is characterized by progressive myocardial remodeling, altered myocyte calcium (Ca 2+ ) handling and deteriorating cardiac function (7) . Intracellular Ca Once believed to be contraindicated for heart failure, β-blockers are now known to be beneficial for patients with mild-to-moderate dilated and ischemic cardiomyopathy (7, 28, 26) .
Contractile dysfunction of patients with dilated cardiomyopathy is normalized through chronic (>8 months) β-adrenergic receptor blockade. It is possible that β-adrenergic receptor blockade indirectly normalizes Ca 2+ regulatory proteins resulting in improved intracellular Ca 2+ cycling in turn reversing cardiac dysfunction (7, 28) . However, the temporal progression of changes in Ca 2+ dynamics and Ca 2+ regulatory proteins at the beginning states of β-blocker therapy remain unknown.
The tropomodulin overexpressing transgenic (TOT) mouse is an experimental model for dilated cardiomyopathy, exhibiting poor hemodynamics, sarcomeric remodeling, ventricular wall thinning, and altered Ca 2+ transients comparable to those in human heart failure (7, 45) .
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MATERIALS AND METHODS
Heart Failure Model. TOT FVB/N mice 4-6 weeks of age were injected intraperitoneally with (N=25) or without (N=25) propranolol (Wyeth-Ayerst) totaling 5 mg/kg/day for 14 days. NTG mice (N=15) served as controls. For long term β-blockade experiments, propranolol or metoprolol (both from Sigma Chemicals, St. Louis MO) were administered in tap water (both at 0.5g/L) that was refreshed every third day.
Myocyte Isolation and Fluo-3 AM loading. Hearts were excised from isoflurane anesthetized FVB/N normal mice and cannulated onto a modified Langendorff perfusion apparatus. Hearts were perfused in low Ca were measured by rapid line-scan confocal microscopy (Molecular Dynamics CLSM 2010) using 40x/1.40 oil objective. Image analysis was performed using Imagespace software (version 3.2) on a Silicon Graphics Indy platform (Silicon Graphics, Mountain View, CA). Linescans were performed at 100Hz. Myocytes were field-stimulated using parallel platinum wires by 7 msec pulses 20% above threshold. Ca Protein immunoblot analysis. Hearts were collected from mice at 6-8 weeks of age.
The hearts were frozen in liquid nitrogen, pulverized, and suspended in lysis buffer (10 mmol/L Tris-HCl, 5 mmol/L EDTA, 50 mmol/L NaCl, 30 mmol/L Na-pyrophosphate, 50 mmol/L NaF, 100 µmol/L Na-orthovanadate, 1% Triton X-100, 1 mmol/L PMSF, 10 nmol/L cypermethrin, 10 nmol/L okadaic acid, 100 µmol/L phenylarsine oxide, 1 mmol/L DTT, 10 µg/mL pepstatin, 10 µg/mL leupeptin, 10 µg/mL aprotinin, 10 µg/mL TLCK, 10 µg/mL TPCK) and sonicated. 50 Ribonuclease protection assay. Measurement of mRNA levels of selected K + channel isoforms was performed using a ribonuclease (RNase) protection assay as described (50).
Statistics.
Results are expressed as mean values ± standard errors. Comparisons between groups were evaluated using ANOVA, with p<0.05 considered significant. Conversely, SERCA protein content was reduced by 3.6 fold in untreated TOTs ( Figure 5C and D). β-blockade treatment of TOTs restored SERCA ( Figure 5C and D) and NCX ( Figure   5A and B) levels to normal levels. Identical propranolol treatment of normal mice had no effect upon SERCA or NCX protein levels (data not shown). These findings are in agreement with other studies that report improved SERCA and NCX levels following β-blockade in different heart failure models (19, 28, 47 
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